undamentalytics Newsletter
Sign in

Pediatrix Medical Group, Inc. (MD) stock

Add to watchlist

Add holding +

NYSE: MD NYSE Hospitals Next results ~January 18, 2027

B Fundamentals grade

Pediatrix Medical Group, Inc. is a US-listed company in the hospitals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$44

Cash-flow model

Base case. Range ~$32–$59 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 42% above it.

Price used: $30.71, November 2, 2026

Pediatrix Medical Group, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds148 adding, 133 cuttingOf 43 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Pediatrix Medical Group files

10-Q filed October 29: Pediatrix Medical

Model value +10.4%

Revenue for the twelve months to September 2026 was $1.96bn, up 1.9% on a year earlier, faster than the 0.5% growth a quarter earlier. Free-cash-flow margin fell to 10.7% from 14.2% a year earlier. The diluted share count is down 2.8% on a year earlier, which lifts each remaining share. Our model value rises from $38.66 to $42.69 a share, against a share price of $29.07. The rating stays Buy. At that price, our model says the market is pricing in cash flow shrinking about 4.1% a year for five years, slower than the 0.5% a year revenue growth it has delivered.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-Q filed August 4: Pediatrix Medical

Pediatrix Medical Group generated revenue of $1.96bn in the twelve months to June 2026, up 1.9% on a year earlier and an acceleration from the 0.5% growth recorded a quarter earlier. Free-cash-flow margin, however, slipped to 10.7% from 14.2% a year earlier. A 2.8% reduction in the diluted share count over the same period has lifted the value attributable to each remaining share. Our model puts fair value at $38.66 a share, little changed, against a current share price of $28.91. We move the rating from Hold to Buy. At the present price, the market appears to be pricing in cash flow shrinking by about 2.7% a year for five years, a gloomier outlook than the 0.5% annual revenue growth the company has actually delivered.

10-Q on SEC EDGAR

Where Pediatrix Medical stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.95bn, up 0.5% on a year earlier, against a decline of 2.3% a quarter earlier. Free-cash-flow margin held at 11.7%. Operating margin widened to 11.0% from 8.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 4 of our 7 financial-health checks. Our cash-flow model value is $38.61 a share, against a share price of $28.92. At that price, our model says the market is pricing in cash flow shrinking about 2.6% a year for five years, slower than the 0.4% a year revenue growth it has delivered.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 18, 2027 (estimated)

Pediatrix Medical Group, Inc.'s trailing-twelve-month revenue grew 1.9% year on year, with a free-cash-flow margin of 10.7%. Where it stands out: change in growth rate of +1.4pp ranks 1 of 5 hospitals companies we cover.

Our discounted-cash-flow model values the business at ~$44 per share in the base case (~$32–$59 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 23.3% while net income fell 7.5%: a 16pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $30.71 is 42% below our value per share of $44.
  • Shrinking share count. Diluted shares fell 2.8% in a year, so each share owns more of the business.

Things to watch

  • Below peers: revenue growth. Revenue growth of 1.9% ranks 4 of 5 hospitals companies we cover (median 3.3%).
  • Below peers: days sales outstanding. Days sales outstanding of 43 days ranks 4 of 5 hospitals companies we cover (median 43 days).

Latest results: FY2026 Q3

Filed October 29, 2026
Earnings per share
$0.72 against an average estimate of $0.65: beat by 10.8%
Revenue
$501m, up 1.7% on a year earlier
Share reaction
+3.1% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Guidance given
adjusted EBITDA $280m to $300m (full year 2026); net income $147,600 to $162,100 (Year Ended December 31, 2026)
Next report
October 29, 2026; average EPS estimate $0.62

Pediatrix Medical Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.0%
  • 1 week+5.8%
  • 1 month+18.3%
  • This year+43.6%
  • 1 year+81.0%
  • 5 years+13.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2B
Operating margin
10.9%
Net margin
7.7%
EPS (TTM, diluted)
$1.82

Growth

Revenue growth
+1.9%
Change in growth rate
+1.4 pts
Share count change
−2.8%

Cash

Free cash flow (TTM)
$210M
FCF margin
10.7%
Stock pay % of revenue
1.1%

Earnings

Last results
October 29, 2026
Next results (est.)
January 18, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results
  3. Guidance
  4. Leadership
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Pediatrix Medical Group, Inc. valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 4.1% a year for five years.That is close to the 0.5% a year revenue growth Pediatrix Medical Group has delivered.

  • Priced in-4.1%
  • Last 12 months1.9%
  • 3 years a year-0.9%
  • 5 years a year0.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($30.00, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$44
Price used
$30.00close November 3, 2026
Implied change
▲ +45%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Pediatrix Medical Group, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($214M, FY2026 Q3 TTM), growing 2.1% and 2.1% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$32–~$59 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Pediatrix Medical Group, Inc.'s free cash flow after stock-based pay ( $214M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Pediatrix Medical Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.76 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$44 ~$32–$59 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: fewer than 5 peers with a usable multiple
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$6.8 ~$4.2–$11 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$5.1 ~$4.3–$6.2 Left out: out of range vs price (0.17x)
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$31 ~$6.8–$44 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Pediatrix Medical Group, Inc. with Health Care sector in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −26%
  • Revenue growth 5 points higher ▲ +34%
  • Free-cash-flow margin 1 point lower ▼ −9%
  • Last year's free-cash-flow margin change, if it persists ▼ −23%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $38$52$70$95$127$169
8.5% $28$39$52$70$93$122
10% $23$31$41$55$72$94

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$66.66$53.44$33.00$27.79$24.54$27.21$14.86$9.30$13.12$21.39$30.71
Market value$6.2bn$5.0bn$3.0bn$2.3bn$2.0bn$2.3bn$1.3bn$764m$1.1bn$1.8bn$2.5bn
+ Net debt (− = net cash)$1.7bn$1.8bn$1.9bn$1.6bn$626m$613m$637m$560m$388m$225m$266m
Enterprise value$7.9bn$6.8bn$5.0bn$4.0bn$2.7bn$2.9bn$1.9bn$1.3bn$1.5bn$2.1bn$2.8bn
Multiples
Price / sales 1.9x1.5x1.8x1.3x1.2x1.2x0.6x0.4x0.5x1.0x1.3x
Price / earnings 19.1x15.5x11.3x——17.8x18.8x——11.0x16.8x
Price / free cash flow 15.3x10.2x10.2x6.9x11.6x52.5x9.1x7.4x5.9x7.2x12.1x
EV / EBITDA 11.9x12.7x18.2x20.1x21.1x12.5x9.1x30.5x—8.9x11.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

47 /100

Moderate moat

How hard Pediatrix Medical Group's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 4 / 20

    Net income has been a median 3.8% of total assets over 10 years.

  • Durability 2 / 20

    Operating margin has been a median 10.4%; its worst year was -10.9%.

  • Cash conversion 14 / 20

    Free cash flow was positive in 8 of 9 years, at a median 9.7% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 3.9% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.38 +17% $2.0bn +3%
Next $2.45 +3% $2.0bn +2%

Next year's EPS estimate has moved +4.0% in 90 days, across 6 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.4% on 90 days ago. In the last 30 days, 5 analysts raised Pediatrix Medical Group, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Pediatrix Medical Group, Inc., last 90 days
$2.25 $2.30 $2.35 $2.40 $2.45 $2.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.28 Current fiscal year, 60 days ago: $2.36 Current fiscal year, 30 days ago: $2.36 Current fiscal year, 7 days ago: $2.36 Current fiscal year, Now: $2.38 $2.38 Next fiscal year, 90 days ago: $2.36 Next fiscal year, 60 days ago: $2.44 Next fiscal year, 30 days ago: $2.44 Next fiscal year, 7 days ago: $2.44 Next fiscal year, Now: $2.45 $2.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.28$2.36
60 days ago $2.36$2.44
30 days ago $2.36$2.44
7 days ago $2.36$2.44
Now $2.38$2.45

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.65 $0.72 +10.8%
Jun 2026 $0.59 $0.63 +6.6%
Mar 2026 $0.38 $0.44 +16.0%
Dec 2025 $0.54 $0.50 −7.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • Adjusted EBITDA full year 2026 $280m to $300m Non-GAAP Maintained
    “Pediatrix reaffirms its full year 2026 outlook for Adjusted EBITDA, as defined above, and anticipates Adjusted EBITDA will be in a range of $280 million to $300 million.” source
  • Net income Year Ended December 31, 2026 $147,600k to $162,100k GAAP
    “Net income $ 147,600 $ 162,100” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Pediatrix Medical Group, Inc.'s revenue by +2.1% next year and +2.1% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+2.1%, weight 64%) and the company's own record (+2.0%, weight 36%) . How the weights are set.

Analyst recommendations

7 analysts, Oct 2026
Buy114%
Hold686%
Sell00%

Monthly trend

  1. Oct 2026167
  2. Sep 2026167
  3. Aug 2026167
  4. Jul 2026257

Counts of recommendations published by analysts covering Pediatrix Medical Group, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.1%
of tradable shares
Days to cover
5.77
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
2.0%
of shares
Employees
4,280
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +81.0%

$16.97 on October 31, 2025 to $30.71

ThenNowEffect
Revenue (last 12 months) $1.9bn $2.0bn +0.5%
Net margin 5.7% 9.0% +58.2%
P/E multiple 13.0x 14.7x +13.0%
Share count 84m 84m +0.7%

Biggest factor: net margin.

Last 3 years +210.2%

$9.90 on November 3, 2023 to $30.71

ThenNowEffect
Revenue (last 12 months) $2.0bn $2.0bn −2.2%
Net margin 5.2% 9.0% +73.8%
P/E multiple 7.9x 14.7x +85.2%
Share count 83m 84m −1.4%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MD+11%−45%−37%+41%+63%+44%
Industry peers (median)+79%−40%+13%+39%+10%+32%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MD50%42%42%67%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MD−31%−48%−50%−33%−31%−17%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 91% from July 12, 2016 to June 11, 2024. Getting back needed a 1027% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$18.82 – $30.71
From 52-week high
0.0%
vs 50-day average
+13.7%
vs 200-day average
+28.4%
Volatility (1 year)
42%
Beta vs S&P 500
0.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±12.7%
After a week
9 up, 2 down
typical move ±15.2%
After a month
9 up, 2 down
typical move ±16.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 +3.1% −2.1% — —
August 4, 2026 −1.0% +1.6% −0.4% +2.3%
July 15, 2026 +9.2% −0.1% +7.1% +9.4%
May 5, 2026 −0.9% +2.2% +5.7% −0.2%
February 19, 2026 −14.3% +0.5% −9.6% −10.3%
November 3, 2025 +26.3% −1.0% +33.0% +37.2%
August 5, 2025 +17.4% +0.3% +19.7% +38.3%
May 6, 2025 +10.8% −0.4% +11.4% +7.5%
February 20, 2025 +10.6% −2.1% +6.7% +0.7%
January 13, 2025 +9.8% +0.3% +12.5% +14.5%
November 1, 2024 +22.9% +0.2% +27.9% +20.3%
August 6, 2024 +26.4% +0.2% +32.7% +40.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Pediatrix Medical Group, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Pediatrix Medical Group, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Pediatrix Medical Group, Inc.
$1.9B $2B $2B $2.1B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $2B Revenue (TTM), FY24 Q1: $2B Revenue (TTM), FY24 Q2: $2B Revenue (TTM), FY24 Q3: $2B Revenue (TTM), FY24 Q4: $2B Revenue (TTM), FY25 Q1: $2B Revenue (TTM), FY25 Q2: $1.9B Revenue (TTM), FY25 Q3: $1.9B Revenue (TTM), FY25 Q4: $1.9B Revenue (TTM), FY26 Q1: $1.9B Revenue (TTM), FY26 Q2: $2B Revenue (TTM), FY26 Q3: $2B $2B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $2B
FY24 Q1 $2B
FY24 Q2 $2B
FY24 Q3 $2B
FY24 Q4 $2B
FY25 Q1 $2B
FY25 Q2 $1.9B
FY25 Q3 $1.9B
FY25 Q4 $1.9B
FY26 Q1 $1.9B
FY26 Q2 $2B
FY26 Q3 $2B
Revenue growth, TTM YoY Pediatrix Medical Group, Inc.
-6% -4% -2% 0% 2% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 1.1% Revenue growth, TTM YoY, FY24 Q1: 0.9% Revenue growth, TTM YoY, FY24 Q2: 0.4% Revenue growth, TTM YoY, FY24 Q3: -0.3% Revenue growth, TTM YoY, FY24 Q4: 0.9% Revenue growth, TTM YoY, FY25 Q1: -1.1% Revenue growth, TTM YoY, FY25 Q2: -3.1% Revenue growth, TTM YoY, FY25 Q3: -4.2% Revenue growth, TTM YoY, FY25 Q4: -4.9% Revenue growth, TTM YoY, FY26 Q1: -2.3% Revenue growth, TTM YoY, FY26 Q2: 0.5% Revenue growth, TTM YoY, FY26 Q3: 1.9% 1.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 1.1%
FY24 Q1 0.9%
FY24 Q2 0.4%
FY24 Q3 -0.3%
FY24 Q4 0.9%
FY25 Q1 -1.1%
FY25 Q2 -3.1%
FY25 Q3 -4.2%
FY25 Q4 -4.9%
FY26 Q1 -2.3%
FY26 Q2 0.5%
FY26 Q3 1.9%
Operating margin (TTM) Pediatrix Medical Group, Inc.
-20% -10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 0.4% Operating margin (TTM), FY24 Q1: -0.3% Operating margin (TTM), FY24 Q2: -10.6% Operating margin (TTM), FY24 Q3: -10.9% Operating margin (TTM), FY24 Q4: -3.4% Operating margin (TTM), FY25 Q1: -2.7% Operating margin (TTM), FY25 Q2: 8.5% Operating margin (TTM), FY25 Q3: 10.4% Operating margin (TTM), FY25 Q4: 10.9% Operating margin (TTM), FY26 Q1: 11.3% Operating margin (TTM), FY26 Q2: 11.0% Operating margin (TTM), FY26 Q3: 10.9% 10.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 0.4%
FY24 Q1 -0.3%
FY24 Q2 -10.6%
FY24 Q3 -10.9%
FY24 Q4 -3.4%
FY25 Q1 -2.7%
FY25 Q2 8.5%
FY25 Q3 10.4%
FY25 Q4 10.9%
FY26 Q1 11.3%
FY26 Q2 11.0%
FY26 Q3 10.9%
FCF margin (TTM) Pediatrix Medical Group, Inc.
0% 5% 10% 15% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 5.2% FCF margin (TTM), FY24 Q1: 4.1% FCF margin (TTM), FY24 Q2: 5.0% FCF margin (TTM), FY24 Q3: 5.7% FCF margin (TTM), FY24 Q4: 9.2% FCF margin (TTM), FY25 Q1: 9.8% FCF margin (TTM), FY25 Q2: 11.7% FCF margin (TTM), FY25 Q3: 14.2% FCF margin (TTM), FY25 Q4: 13.2% FCF margin (TTM), FY26 Q1: 12.3% FCF margin (TTM), FY26 Q2: 11.7% FCF margin (TTM), FY26 Q3: 10.7% 10.7%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 5.2%
FY24 Q1 4.1%
FY24 Q2 5.0%
FY24 Q3 5.7%
FY24 Q4 9.2%
FY25 Q1 9.8%
FY25 Q2 11.7%
FY25 Q3 14.2%
FY25 Q4 13.2%
FY26 Q1 12.3%
FY26 Q2 11.7%
FY26 Q3 10.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Pediatrix Medical Group took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $1.9B
  2. Selling, general and admin $241M · 12.6%
  3. Other operating costs $1.5B · 76.5%
  4. Operating income $209M · 10.9%
  5. Income tax $51M · 2.7%
  6. Net income $165M · 8.6%

Shares of revenue. Source: Pediatrix Medical Group's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 3,183 3,253 1,723 1,780 1,734 1,911 1,972 1,995 2,013 1,914 1,959
EBITDA 661 534 273 198 127 235 208 43 −36 231 236
Operating income 572 455 248 172 98 203 173 7 −69 209 213
Net income 325 320 269 −1,498 −796 131 66 −60 −99 165 150
Diluted EPS $3.49 $3.45 $2.93 −$17.83 −$9.55 $1.53 $0.79 −$0.73 −$1.19 $1.94 $1.82
Growth (year on year)
Revenue — +2.2% −47.0% +3.3% −2.6% +10.2% +3.2% +1.1% +0.9% −4.9% +1.9%
EBITDA — −19.2% −48.9% −27.5% −36.0% +85.7% −11.4% −79.1% −183.9% — +6.3%
Operating income — −20.4% −45.4% −30.9% −42.9% +106.8% −14.9% −95.8% — — +6.7%
Net income — −1.4% −16.2% −657.5% — — −49.3% −191.1% — — −7.5%
Diluted EPS — −1.1% −15.1% −708.5% — — −48.4% −192.4% — — −4.8%
Margins
EBITDA margin 20.8% 16.4% 15.8% 11.1% 7.3% 12.3% 10.6% 2.2% −1.8% 12.1% 12.1%
Operating margin 18.0% 14.0% 14.4% 9.7% 5.7% 10.6% 8.8% 0.4% −3.4% 10.9% 10.9%
Net margin 10.2% 9.8% 15.6% −84.2% −45.9% 6.9% 3.4% −3.0% −4.9% 8.6% 7.7%
Free-cash-flow margin 12.7% 14.9% 17.2% 19.0% 10.1% 2.3% 7.0% 5.2% 9.2% 13.2% 10.7%
Cash flow
Cash from operations 444 511 314 358 205 77 167 137 207 271 227
Capital spending 39 26 17 19 29 32 30 33 22 18 17
Free cash flow 405 485 297 338 176 44 137 104 185 253 210
Stock-based pay 34 29 37 33 39 19 16 12 12 18 21
Free cash flow after stock pay 371 456 260 305 137 26 121 92 173 235 188
Balance sheet
Cash 56 40 41 108 1,124 387 10 73 230 375 312
Total debt 1,714 1,861 1,990 1,750 1,750 1,000 647 633 618 600 578
Net debt (negative = net cash) 1,658 1,820 1,949 1,642 626 613 637 560 388 225 266
Diluted shares 93m 93m 92m 84m 83m 86m 84m 82m 83m 85m 82m
Returned to shareholders
Buybacks 62 70 302 145 8 5 89 1 2 87 211
Total returned 62 70 302 145 8 5 89 1 2 87 211

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · September 30, 2026
What it owns · $2.1bn
Short-term assets $684mLonger-term assets $1.5bn
What it owes, and who funded it · $2.1bn
Short-term liabilities $536mLonger-term liabilities $754mShareholders' equity $850m
  • Short-term assets cover short-term liabilities $684m of assets due within a year against $536m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $684m short-term assets against $754m of longer-dated liabilities.
  • More cash than debt $312m of cash against $398m of debt.
  • Debt below 40% of shareholders' equity Debt is 47% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 113% to 47% over five years.
  • A year's operating cash flow covers at least 20% of debt $227m of operating cash flow against $398m of debt.
  • Operating profit covers interest at least five times over Operating income of $213m against $33m of interest.

From Pediatrix Medical Group, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$211M
Returned to shareholders
101%
of free cash flow
Buybacks, last 3 fiscal years
$89.3M
Diluted share count
−2.8%
year over year
Total shareholder yield
8.8%
dividends 0.0% + buybacks 8.8% of market value
Days sales outstanding
43 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in hospitals
Last 12 months unless stated MD EHC ARDT CYH THC Median
Revenue, last 12 months $2.0bn $6.2bn $6.4bn $11.7bn $22.2bn $6.4bn
Revenue growth, last 12 months 1.9% 9.5% 3.3% −7.8% 6.2% 3.3%
Revenue growth, 3-year average −0.9% 10.7% — −2.2% 3.2% 1.2%
Revenue growth, latest quarter 1.7% 9.6% −1.4% −10.7% 6.5% 1.7%
Operating margin 10.9% 12.4% — 10.9% 24.4% 11.6%
Operating margin, 3-year average 3.4% 12.8% — 8.7% 23.0% 10.7%
Net margin 7.7% 10.0% 1.2% 0.3% 13.1% 7.7%
Cash from operations / revenue 11.6% 19.5% 8.0% 1.8% 19.1% 11.6%
Free-cash-flow margin 10.7% 6.7% 5.5% −1.0% 15.0% 6.7%
Free-cash-flow margin, 3-year average 10.2% 6.2% 3.3% 0.0% 11.2% 6.2%
Stock pay / revenue 1.1% 0.9% — 0.1% 0.6% 0.8%
Change in share count −2.8% −1.0% 1.3% 1.5% −8.4% −1.0%

Median of all 5 companies we cover in hospitals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

5 hospitals companies
Measure Company Peer median Rank
Revenue growth Growth 1.9% 3.3% 4 of 5
Change in growth rate Growth +1.4pp -0.6pp 1 of 5
Net margin Profitability 7.7% 7.7% 3 of 5
Free-cash-flow margin Cash generation 10.7% 6.7% 2 of 5
Long-term debt as % of assets Balance sheet 18.6% 34.8% 1 of 5
Change in share count Balance sheet -2.8% -1.0% 2 of 5
Days sales outstanding Balance sheet 43 days 43 days 4 of 5

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Health Care Patient Service $1.6B 85.2% ▼ 5.4%
Hospitals Contracts $271M 14.2% ▼ 5.4%
Other $12.2M 0.6% ▲ 364.0%

From Pediatrix Medical Group, Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.1B
Institutions reporting
302
Shares held vs prior quarter
▲ 0.7%
Positions opened / closed
38 / 29

Top buyers and sellers, Q2 2026: 148 institutions bought and 133 sold ; the biggest buyer was Allspring Global Investments Holdings, LLC (+644K shares) and the biggest seller American Century Companies Inc (−1.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $347M 13.7M 16.4% ▲ 1.0%
Vanguard Portfolio Management LLC $152M 6.0M 7.2% ▼ 2.7%
Dimensional Fund Advisors LP $107M 4.2M 5.1% ▲ 9.4%
Vanguard Capital Management LLC $91.7M 3.6M 4.3% ▼ 1.0%
State Street Corp $89.5M 3.5M 4.2% ▲ 4.6%
Victory Capital Management Inc $86.6M 3.4M 4.1% ▼ 11.1%
Wasatch Advisors LP $63.3M 2.5M 3.0% ▲ 21.9%
Geode Capital Management, LLC $56.4M 2.2M 2.7% ▲ 1.7%
American Century Companies Inc $55.5M 2.2M 2.6% ▼ 44.2%
Fuller & Thaler Asset Management, Inc. $43.6M 1.7M 2.1% ▲ 40.0%
Allspring Global Investments Holdings, LLC $42.3M 1.6M 2.0% ▲ 66.0%
D. E. Shaw & Co., Inc. $40.9M 1.6M 1.9% ▼ 5.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Pediatrix Medical Group, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.8M 4 trades by 4 insiders · 0% under pre-set plans
Net ▼ $1.8M net selling
Insider Date Trade Shares Price Value
Weis Shirley A Director May 13, 2026 Sell 36,028 $23.75 $855,665
Ordan Mark S Chief Executive Officer December 15, 2025 Sell 23,000 $22.41 $515,430
Rucker Michael A. Director November 17, 2025 Sell 10,478 $23.00 $240,994
Linynsky Laura A Director November 6, 2025 Sell 10,000 $21.65 $216,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 9 trades and filings

No trades in Pediatrix Medical Group, Inc. disclosed in the last 12 months; 9 earlier trades on record.

  • Donna Shalala(FL):Sale (full), $50,001 - $100,000, traded October 15, 2019, filed April 27, 2020
  • Greg Gianforte(MT):Sale (full), $50,001 - $100,000, traded October 26, 2018, filed October 29, 2018
  • Greg Gianforte(MT):Purchase, $100,001 - $250,000, traded January 29, 2018, filed February 8, 2018

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 18, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • August 4, 2026
  • July 15, 2026
  • May 5, 2026
  • February 19, 2026
  • November 3, 2025

Recent SEC filings

Data status

When each part of this page on Pediatrix Medical Group, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Pediatrix Medical Group, Inc. in brief

What does Pediatrix Medical Group, Inc. do?
Pediatrix Medical Group, Inc. is a US-listed company in the hospitals industry. Its financial year ends in December.
What is Pediatrix Medical Group, Inc.'s stock ticker?
Pediatrix Medical Group, Inc. trades under the ticker MD on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Pediatrix Medical Group, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Pediatrix Medical Group, Inc. reported revenue of $2B, 1.9% higher than a year earlier, according to its SEC filings.
What is Pediatrix Medical Group, Inc.'s free cash flow?
Pediatrix Medical Group, Inc.'s free-cash-flow margin is 10.7% of revenue over the trailing twelve months, ranking 2 of the 5 hospitals companies we cover.
What is Pediatrix Medical Group, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Pediatrix Medical Group, Inc.'s free cash flow after stock-based pay gives ~$44 per share in the base case, and ~$32–$59 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Pediatrix Medical Group, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and Dimensional Fund Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Pediatrix Medical Group, Inc. buying back stock, and does it pay a dividend?
Pediatrix Medical Group, Inc. spent $211M on share repurchases over the trailing twelve months, and its diluted share count fell 2.8% over the year.
What is Pediatrix Medical Group, Inc.'s market cap?
On November 2, 2026, Pediatrix Medical Group, Inc.'s market capitalisation was about $2.5B, with a price-to-earnings ratio of 16.8 and net debt of $266M. Market figures come from third-party market data and may be delayed.
How much debt does Pediatrix Medical Group, Inc. have?
Pediatrix Medical Group, Inc.'s debt-to-equity ratio is 46.8%, from its latest balance sheet (112.8% five years earlier). The financial health section below sets out its other solvency checks.
Who are Pediatrix Medical Group, Inc.'s competitors?
In our Hospitals peer group, the companies closest to Pediatrix Medical Group, Inc. are Encompass Health Corp, Ardent Health, Inc., Community Health Systems Inc and Tenet Healthcare Corp. The side-by-side comparison below sets their revenue, margins and growth against Pediatrix Medical Group, Inc.'s.
Are insiders buying or selling Pediatrix Medical Group, Inc. stock?
Over the last 12 months, Pediatrix Medical Group, Inc.'s directors and officers reported 0 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Pediatrix Medical Group, Inc.'s next earnings date?
Around January 18, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Pediatrix Medical Group, Inc. announces its own schedule.